Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.53 |
| ▸ | TP53 | P04637 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471479 | 0.95 | MAPT (0.49) | MAPTTP53ALDH1A1POLBNPC1 | |
| SCHEMBL2472568 | 0.93 | TP53 (0.49) | MAPTTP53ALDH1A1POLBNPC1 | |
| SCHEMBL2470655 | 0.90 | MAPT (0.49) | MAPTTP53ALDH1A1POLBNPC1 | |
| SCHEMBL2466069 | 0.86 | ALDH1A1 (0.47) | MAPTTP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2472074 | 0.85 | TP53 (0.53) | MAPTTP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2469736 | 0.84 | MAPT (0.46) | MAPTTP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2471727 | 0.84 | TP53 (0.50) | MAPTTP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2469743 | 0.84 | MAPT (0.46) | MAPTTP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2473831 | 0.83 | MAPT (0.45) | MAPTTP53ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL2473905 | 0.81 | TP53 (0.47) | MAPTTP53ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656139-B1 | ARYL DICARBOXAMIDES | MERCK SERONO SA (CH) | 2011-10-05 | — | — | EP | claimed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | claimed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | claimed |
| EP-1904048-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | claimed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | claimed |
| US-20060189583-A1 | Aryl dicarboxamides | MERCK SERONO SA (CH) | 2006-08-24 | — | — | US | claimed |
| EP-1656139-A1 | ARYL DICARBOXAMIDES | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-17 | — | — | EP | claimed |
| WO-2005011685-A1 | ARYL DICARBOXAMIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | claimed |
| EP-1904048-B1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | MERCK SERONO SA (CH) | 2011-11-23 | — | — | EP | disclosed |
| EP-1656139-B1 | ARYL DICARBOXAMIDES | MERCK SERONO SA (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | disclosed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | disclosed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | disclosed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | disclosed |
| EP-1904048-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20060189583-A1 | Aryl dicarboxamides | MERCK SERONO SA (CH) | 2006-08-24 | — | — | US | disclosed |
| EP-1656139-A1 | ARYL DICARBOXAMIDES | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005011685-A1 | ARYL DICARBOXAMIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189583-A1 | Aryl dicarboxamides | GPR119, PTPRS, ECHS1 | MAPT 4883/4885TP53 1795/4885ALDH1A1 1704/4885 |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | PPP1R1B, PPP5C, PPP3CA | MAPT 2586/4885TP53 3050/4885ALDH1A1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.